NORTHWEST BIOTHERAPEUTICS INC (NWBO)
Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform. This platform harnesses a patient's own activated dendritic cells to stimulate their immune system to combat cancerous cells. The company's leading therapeutic candidate, DCVax-L, has successfully completed Phase III clinical trials targeting Glioblastoma multiforme, an aggressive form of brain cancer. Additionally, Northwest Biotherapeutics is progressing DCVax-Direct through Phase I/II clinical studies, focusing on the treatment of inoperable solid tumors. Founded in 1996, the company's headquarters are situated in Bethesda, Maryland.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Northwest Biotherapeutics, Inc.
| Form | Description | Links | |
|---|---|---|---|
| 10-Q | |||
| 8-K | |||
| 10-Q | |||
| 8-K | |||
| 424B5 | |||
| 8-K | |||
| 10-Q | |||
| EFFECT | |||
| POS AM | |||
| 10-K | |||
| 8-K | |||
| NT 10-K | |||
| 8-K | |||
| 8-K | |||
| DEF 14A | |||
| EFFECT | |||
| 424B5 | |||
| CORRESP | |||
| 8-K | |||
| PRE 14A | |||
| 10-Q | |||
| 8-K | |||
| 8-K | |||
| 8-K | |||
| S-3 |
1-25 of 804 filings
Recent SEC filings with analysis
- 10-QNorthwest Biotherapeutics reported a Q3 2026 net loss of $28.8 million and a nine-month net loss of $41.1 million, improved from $61.6 million a year earlier,…
- 8-KNorthwest Biotherapeutics entered into a $5,505,000 commercial loan agreement with Streeterville Capital, LLC on October 26, 2026, with proceeds earmarked for…